IL1B and neoplasm: Unlike other inhibitors of the IL-1 pathway, inhibition of IRAK1 with Pacritinib had very little effect on bone metastasis, reducing metastatic outgrowth of disseminated tumour cells in the bone by 12% compared with control, 18 days post tumour injection (Figure 3L,I and Figure S5C).